Karyopharm Therapeutics
KPTI
$1.10
Share price
3.77%
Change (1 day)
-71.43%
Change (1 year)
Categories
Operating Margin for Karyopharm Therapeutics (KPTI)
Operating Margin as of April 2024 (TTM): -90.24%
According to Karyopharm Therapeutics 's latest financial reports and stock price the company's current Operating Margin is -90.24%. At the end of 2021 the company had an Operating Margin of -59.01%.
Operating Margin history for Karyopharm Therapeutics from 2013 to 2023
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2021 | -59.01% | -67.45% |
| 2020 | -181.31% | -62.85% |
| 2019 | -487.98% | -17.01% |
| 2018 | -588.02% | -92.68% |
| 2017 | -8,032.46% | -88.7% |
| 2016 | -71,063.64% | 50.33% |
| 2015 | -47,272.40% | 42.86% |
| 2014 | -33,090.39% | 277.23% |
| 2013 | -8,771.83% | 250.03% |
| 2012 | -2,505.99% | -63.06% |
| 2011 | -6,783.55% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Abbott Laboratories ABT | 15.60% | -117.29% | 🇺🇸 USA |
 Merck MRK | 27.73% | -130.73% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 19.24% | -121.32% | 🇺🇸 USA |
 Exelixis EXEL | 11.86% | -113.14% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.